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NG-NITRO-L-ARGININE methyl  ester  (L-NAME)  has  been
used  extensively as  a  paradigmatic  inhibitor  of  NO
synthase and has been shown to cause antinocicep-
tion  in  several  experimental  models.  We  describe
here how L-NAME  produced a dose-dependent  anti-
nociceptive effect when injected intraperitoneally in
the  mouse  after  acetic  acid  induced  writhings,  or
intraplantarly in the rat  paw pressure hyperalgesia
induced  by  carrageenin  or  prostaglandin  E2.  In
contrast  another  NO  synthase  inhibitor,  NG-mono-
methyl-L-arginine (L-NMMA), had no significant effect
per se but inhibited L-NAME  systemic induced anti-
nociception in mice and local induced antinocicep-
tion in the rat paw hyperalgesia test. D-NAME had no
antinociceptive  effect  upon  carrageenin-induced
hyperalgesia.  Pretreatment  of  the  paws  with  two
inhibitors of guanylate cyclase, methylene blue (MB)
and  1H-:[1,2,4]-oxadiazolo-:[4,3-a]  quinoxalin–1-one
(ODQ)  abolished  the  antinociceptive  effect  of
L-NAME. L-Arginine and the cGMP phosphodiesterase
inhibitor, MY 5445 significantly enhanced the L-NAME
antinociceptive  effect.  The  central  antinociceptive
effect of L-NAME was blocked by co- administration of
L-NMMA, ODQ and MB. The present series of experi-
ments shows that L-NAME, but not L-NMMA,  has an
antinociceptive  effect.  It  can  be  suggested  that
L-NAME causes the antinociceptive effect by stimula-
tion of  the arginine/ NO/ cGMP pathway,  since the
antinociceptive effect of L-NAME can be antagonized
by L-NMMA  and abolished  by the guanylate cyclase
inhibitors (MB  and ODQ).  In addition,  the  NO  syn-
thase  substrate,  L-arginine and  the  cGMP  phospho-
diesterase inhibitor, MY5445 were seen to potentiate
the effects of L-NAME. Thus, L-NAME used alone, has
limitations as a specific inhibitor of the arginine-NO-
cGMP pathway and may therefore be a poor pharma-
cological tool for use in characterising participation
in pathophysiological processes.
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Introduction
L-NAME (NG-nitro-L-arginine methyl ester), has been
shown  to  cause  antinociception  by  spinal,  supra-
spinal,  local  (intraplantar)  or  systemic  administra-
tion.1–8 As  L-NAME  is  considered  an  specific  nitric
oxide (NO) synthase inhibitor,2,24 these experiments
were taken to support the hypothesis that stimulation
of  the  arginine/NO/cGMP  pathway  enhances  noci-
ception at  various levels of the sensory system. On
the other hand, there are several reports indicating
that  cholinergic  or  opioidergic  stimulation  of  the
arginine/NO/cGMP pathway causes central, spinal or
peripheral analgesia,9–12 and some peripheral analge-
sics  cause  antinociception  by  stimulation  of  this
pathway.13 –16 Furthermore,  the  central  analgesic,
arginine,  seems  to  be  associated  with  NO-cGMP
stimulation.17–19Thus there appears to be an apparent
contradiction amongst the various experiments made
to  ascertain  the  role  of  the  arginine/NO/cGMP
pathway in nociception. A great deal of information
has  been  derived  with  the  use  of  L-NAME  as  a
methodological tool. However L-NAME can be seen to
be either analgesic or hyperalgesic in the same test20
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Mediators of Inflammation, 9, 25–30 (2000)whilst  another  NO  synthase  inhibitor  NG-monome-
thyl-L-arginine (L-NMMA) does not show antinocicep-
tion in the same test as L-NAME, i.e. the formalin test
in  mice.2 Recently,  L-NAME  has  been  reported  to
stimulate inducible NO synthase (iNOS) gene expres-
sion.21 Because  of  these  apparent  contradictory
results, we evaluated the possibility that the analgesic
effect  of  L-NAME  was  due  to  stimulation  of  the
arginine/NO/cGMP  pathway.  In  the  present  study
L-NAME  was  initially  assayed in  two  tests  in  which
nociception  involves  an  inflammatory  stimulus:  the
acetic acid induced writhings in mice and in the rat
paw  pressure  hyperalgesia  test  induced  by  intra-
plantar administration of carrageenin. In these tests
L-NAME showed an antinociceptive effect which was
significantly inhibited by pretreatment of the animals
with L-NMMA.
To further investigate the antinociceptive effect of
L-NAME and in order to avoid the oedema formation
and  facilitate  successive  injections  of  drugs,  PGE2
instead  of  carrageenin  was  used  to  induce  hyper-
algesia  in the rat paw pressure test. In this test the
peripheral  antinociceptive  synergism  between
L-NAME and the NO synthase substrate, arginine, and
the  cGMP  phosphodiesterase  inhibitor,  as  well  the
effect of two inhibitors of guanylate cGMP activation,
methylene  blue  (MB)  and  1H-[1,2,4]-oxadiazolo-
[4,3-a]  quinoxalin–1-one  (ODQ)  was  evaluated.
Finally,  since  L-NAME  has  been  shown  to  cause
analgesia  by  intracerebroventricular administration,2
we tested L-NAME co-administration with inhibitors




The experiments were performed on male Wistar rats
(150–180 g)  and  albino  Swiss  mice  (22–30 g). The
animals were  housed  under  natural  light, with  free
access  to  food  and  water.  Intracerebroventricular
(i.c.v.)  injections  in  rats  were  made  following  the
method  described  by  Cˆ orrea  and  Graeff.22 When
single  doses  of  the  various  drugs  were  used,  they
were based on dose response pilot experiments. All
experimental  procedures  conformed  to  the  IASP
guidelines on the use of animals in pain research. Rats
were used once only.
Nociception tests
(a ) Writhing test in mice.
This test was based on the frequency of abdominal
contortions evoked by an intraperitoneal injection of
10 ml/kg of 0.6% acetic acid.8 L-NAME, L-arginine, or
vehicle was injected 15 min before acetic acid admin-
istration,  and  the  number  of  writhing  events  were
counted  for 20 min  after the nociceptive challenge.
For antagonism studies, mice were treated as above,
except that L-NMMA was administered 15 min before
L-NAME.
(b) Hind paw hyperalgesia test in rats.
Our  modification  of  the  Randall-Selitto  rat  paw
pressure test was used to measure hyperalgesia.23 In
the  test,  a  pressure  of  20 mmHg  is  continuously
applied to the hind  paw of the rat until  the animal
presents a typical freezing reaction (reaction  time).
After measurement of the basal reaction time (control),
hyperalgesia  was  induced  either  by  an  intraplantar
injection  of  carrageenin  (Cg,  100 m g)  or  PGE2. The
intensity of hyperalgesia was quantified as the differ-
ence in reaction time (delta reaction time) measured
3 h  after  administration  of  Cg,  from  the  control
reaction time assessed before injection of the hyper-
algesic stimulus. The term nociception is used in this
paper to describe the presence of an overt standard
behaviour  induced  by  the  application  of  a noxious
stimulus in a normal tissue or a non-noxious stimulus in
previously sensitised tissue. The term hyperalgesia is
used when a non-noxious stimulus causes nociception
when  applied  to  a  sensitized  tissue  either  by  an
inflammatory stimulus like carrageenin or an hyper-
algesic mediator like prostaglandin E2.
Drugs
Carrageenin  (Viscarin)  was  purchased  from  Marine
Colloids,  EUA.  L-NAME  (N-nitro-L-arginine  methyl
ester, Wellcome, UK) and L-NMMA (NG-monomethyl-
L-arginine  acetate)  were  purchased  from  Sigma  (St
Louis, MO, USA) and methylene blue (MB) was from
Reagen  (Brazil)  and  ODQ  (1H-[1,2,4]-oxadiazolo-
[4,3-a]  quinoxalin–1-one)  was  from Tocris  Cookson
Inc. (St Louis, USA).
Statistics
All results are presented as means (SEM of five rats or
six  to 12  mice per group. Results are  presented as
means and standard errors of the means of groups of
at  least  five  animals  in  each  group.  Differences
between  responses  were  evaluated  by ANOVA,  fol-
lowed by the Bonferroni t-test. Results with P<0.05
were considered significant.
Results
Blockade of L-NAME effect by L-NMMA in two
tests of nociception induced by inflammatory
stimuli
(a) Mice writhing test: nociceptive behaviour induced
by intraperitoneal acetic acid administration.L-NAME
administered intraperitoneally reduced the number of
abdominal constrictions in a dose-dependent manner
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FIG.  1.  Inhibition by  L-NMMA  (10mg/kg,  i.p.)  of  the  anti-
nociceptive  effect  of  intraperitoneal  administration  of
L-NAME on the acetic acid writhing test in mice. The symbols
are  the  mean  ±  SEM  of  6–12  mice/group.  *indicates  sig-
nificant differences (P < 0.05) in comparison with the control
L-NAME group treated with intraperitoneal saline.
FIG. 2. Antinociceptive effect of intraplantar administration
of  L-NAME  but  not  of  D-NAME  on  carrageenin-induced
hyperalgesia and the blockade of  antinociception by local
L-NMMA  and  methylene  blue  (MB)  co-administration.
L-NMMA (100 m g/paw), MB (500 m g/paw) or saline (S) were
injected  30min  before  carrageenin  (Cg,  100 m g/paw).
L-NAME  or  D-NAME  (50–300 m g/paw)  were  also  injected
30min  before  Cg,  and  the  intensity  of  hyperalgesia  was
measured 3h after the hyperalgesic stimulus (see injections
diagram). The symbols  are the  mean + SEM of  five  rats/
group. *indicates significant differences (P < 0.01) in compar-
ison with the control (saline, O) or treatment with L-NAME,
MB, D-NAME.
FIG.  3.  Blockade  by  L-NMMA  (LN)  and  guanylate cyclase
inhibitors  (MB  and  ODQ)  of  the  antinociceptive  effect  of
L-NAME on PGE2 induced hyperalgesia. PGE2 was injected at
time  zero,  saline  (S)  or  LN,  MB,ODQ,  at  time  1.5h  and
L-NAME  or  S  2h  after  PGE2.  The  insert  shows  the  anti-
nociceptive effect of L-NAME (60 = a, 180 = b and 300 m g per
paw = c).The bars and symbols are the mean ± SEM of five
rats/group. The asterisks  mean significant differences (P <
0.05): (a)  *in  comparison  with  the  control  PGE2;  (b)  **in
comparison with L-NAME-treated groups.
by approximately 40% and 73% at  doses of  30  and
90 mg/kg, respectively. L-NMMA (10 mg/kg i.p.), sig-
nificantly  blocked  the  antinociceptive  action  of
L-NAME, but had no effect on its own (Fig. 1).
(b) Rat paw pressure test: hyperalgesia induced by
carrageenin inflammation.
Intraplantar administration of L-NAME (50 and 300 m g)
produced  a  significant  inhibition  of  carrageenin-
induced hyperalgesia of up to 40% for the highest dose
used (Fig. 2). L-NAME-induced peripheral hyperalgesia
was  significantly  inhibited  by  pre-treatment  of  the
paws with 100 m g of L-NMMA or 500 m g of MB. Neither
MB, nor L-NMMA (up to 500 m g /paw ) had hyperalgesic
effects.
Rat paw pressure test: hyperalgesia induced by
PGE2
(a ) Antagonism L-NMMA, MB or ODQ of
L-NAME-induced antinociception.
Pilot  experiments  showed  that  doses  higher  than
200 m g/paw  were  needed  to  give  significant  anti-
nociception. Fig. 3 shows a significant antinociceptiveeffect upon hyperalgesia induced by PGE2 of a dose of
300 m g  of  L-NAME.  Pretreatment  of  the  paws  with
L-NMMA  (LN),  MB  or  ODQ  prevented  the  anti-
nociceptive effect of L-NAME.
(b) Arginine and MY 5445 enhancement of
L-NAME effects.
Figure 4 shows that the association of L-arginine and
L-NAME treatments caused a significant antinocicep-
tion compared with single treatments. There was no
difference  among  controls  groups.  L-NMMA  signifi-
cantly  inhibited  the  antinociceptive  effect  of  the
association of L-arginine and L-NAME treatment. The
association  of  the  same  doses  of  L-NAME  and
D-arginine did not cause antinociception as compared
with the single treatment (data not shown).
Figure 5 shows that MY 5445 enhanced, in a dose-
related manner, the antinociceptive effect of L-NAME.
A dose of 180 m g, which did not produce antinocicep-
tion in our experiments, produced an effect similar to
300 m g when the paws were pretreated with MY 5445
(compare with Fig. 3).
(c) Blockade of the intracerebroventricular
antinociceptive effect of L-NAME by co-treatment
with L-NMMA, MB or ODQ.
L-NAME, when administered i.c.v. at a dose of 300 m g
per  rat,  produced  potent  antinociception  in  paws
rendered hyperalgesic by PGE2 (Fig. 6). This L-NAME-
induced anti-hyperalgesic effect was abolished by co-
i.c.v.  administration  of  L-NMMA  (300 m g),  MB
(400 m g) and ODQ (8 m g). Neither L-NMMA, nor MB,
nor  ODQ  had  any  effects  on  PGE2 induced
hyperalgesia.
Discussion
L-NAME has been shown by several laboratories1–8 to
have a peripheral and central antinociceptive action.
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FIG.  4.  Antinociceptive  synergism  between  L-NAME  and
L-arginine.  The  measurements  were  made  3h  after  the
intraplantar  injections  of  PGE2 (100ng/paw).  L-NMMA,
L-Arginine (L-Arg) and L-NAME were injected into the paw 1,
1.5 and 2h after the PGE2 challenge, respectively. The bars
are the mean ± SEM of five rats/group. The asterisks mean
significant differences (P < 0.05): (a) *in comparison with the
control PGE2 treated either with L-arg, L-NAME, or saline (S);
(b) **in comparison with the group which received L-NMMA
+ L-arg + L-NAME.
FIG. 5. Potentiation of intraplantar injections of L-NAME by
the cGMP phosphodiesterase inhibitor, MY 5445. The meas-
urements were made 3h after the intraplantar injections of
PGE2 (100ng/paw). MY 5445 and (or) L-NAME were injected
into the paw 1 and 2h after PGE2, respectively. The bars are
the  mean  ±  SEM  of  five  rats/group.  The  asterisk  means
significant differences (P < 0.05) compared with respective
doses  of  L-NAME.  There  was  no  significant  differences
between the controls groups (C) treated with saline or MY
5445.
FIG.  6.  Antinociceptive  effect  of  intracerebroventricular
administration of L-NAME (N
G-nitro-L-arginine methyl ester)
on  PGE2-induced  hyperalgesia,  and  its  blockade  by  i.c.v.
L-NMMA  (LN,  300 m g,), MB  (400 m g)  or  ODQ  (8 m g). These
drugs and vehicle were co-injected with L-NAME 2h after
PGE2 (100ng/paw). The intensity of hyperalgesia was meas-
ured 1h  after the i.c.v. injections. The bars  are the mean,
SEM of five rats/group. *,**mean significant differences (P <
0.01) in comparison with the saline- (Sal) or L-NAME-treated
group, respectively.Here, we confirm their observations using two tests
of  nociception.  In  the  acetic  acid  writhing  test,
systemic  administration  (i.p.)  of  L-NAME  but  not
L-NMMA caused an antinociceptive effect (Fig. 1). In
addition,  we  showed  that  L-NMMA  inhibited  the
antinociceptive activity of L-NAME in this test as well
as in the rat paw pressure test in which hyperalgesia
was induced either by an inflammatory stimuli like Cg
or by an hyperalgesic mediator, PGE2 (Figs 2–4). The
D-isomer of NAME showed no antinociceptive activity
(Fig. 2) in carrageenin-induced hyperalgesia in the rat
pressure tests (Fig. 2). It has already been shown that
this  isomer  had  no  antinociceptive  effect  in  other
tests.2 Co-injection of L-NMMA i.c.v. also inhibited the
central analgesic action of L-NAME (Fig. 6).
The  observed  antinociceptive  effect  of  L-NAME
apparently  supports  the  idea  that  the  arginine/NO/
cGMP  pathway  contributes  to  nociception  induced
by inflammatory stimuli, particularly because L-NAME
is  considered  to  be  a  selective  NO  synthase  inhib-
itor.2,24 L-arginine-derived  inhibitors,  however,  have
been found to have bizarre pharmacological effects.
For instance, it has been demonstrated that L-NAME is
a  poor  inhibitor  of  L-arginine  transport,  whereas
L-NMMA and L-NIO substantially inhibit this event.25
Moreover, L-NAME, but not L-NMMA, is a muscarinic
antagonist.26 On the other hand, L-NMMA, has been
shown  to  behave  as  a  partial  agonist,  since  it
antagonizes NO synthesis in some tissues, but stim-
ulates NO synthesis in isolated arterial rings.27
Since,  in  our experiments,  L-NMMA  in  the  doses
used did not show any effect per se, but blocked the
antinociceptive effect of L-NAME, we assume that it
may  be  acting  as  a  NO  synthase  inhibitor.  On  the
other  hand,  L-NAME  may  be  acting  either  as  a
substrate for or as an iNOS stimulator.
It is known that during carrageenin (but not PGE2 )
induced  hyperalgesia  the  arginine/NO/cGMP  path-
way  is  activated.28 The  absence  of  activity  of  the
arginine NO cGMP pathway in PGE2-induced hyper-
algesia is illustrated here by the fact that neither the
NO synthase inhibitors (MB or ODQ) nor the cGMP
phosphodiesterase inhibitor, MY5445, have any effect
upon control hyperalgesia  (Figs 3–5). Nevertheless,
L-NAME displayed an antinociceptive effect. Recently,
L-NAME  has  been  described  as  acting  as  a  partial
agonist,27 causing  rapid  induction  of  iNOS  gene
expression.21 Stimulation  of  NO  synthesis  may
explain  the  observed  L-NAME  antinociception,  in
models like those used in this investigation. In these
models it has been previously shown that either NO
donors  or  drugs  which  stimulate  the  arginine  NO
cGMP  pathway  cause  analgesia.9,10,13–18 Thus,  the
simplest comprehensive explanation for the fact that
L-NAME  antinociception  was  inhibited  by  a  NO
synthase  inhibitor,  L-NMMA  and  was  abolished  by
guanylate cyclase inhibitors, MB or ODQ as well as
potentiated  by  either  the  NO  synthase  substrate,
arginine or by the cGMP phosphodiesterase inhibitor
MY5445 is that L-NAME is activating iNOS. The fact
that i.c.v. co-injections of MB or ODQ  inhibited the
central  antinociceptive effect  of  L-NAME  suggests  a
similar mechanism of action  for  the peripheral and
central action for this agent.
Finally, it must be pointed out that, in contrast with
the results presented here, there are several observa-
tions  indicating  that  the  intraplantar  or  systemic
administration of L-NAME has similar effects to other
NO synthase inhibitors in causing antinociception.4,20
This contradiction may explained by considering that
the  activation  of  the  arginine/NO/cGMP  pathway
causes  hyperalgesia  or  analgesia  depending  on  the
predominant  type  of  fibres  involved  in  the  noci-
ceptive response or depending on the tissue level of
NO.20 From the therapeutic point of view, however, it
seems  that  during  inflammatory  pain  in  man,  the
activation of the arginine/NO/cGMP pathway causes
analgesia. This suggestion is in line with the observa-
tions that NO donors are either effective as analgesics
by  themselves  or  in  conjunction  with  other
analgesics.29–32
In  conclusion,  the  present  study  confirms  that
L-NAME  causes  analgesia  and  demonstrated  that
L-NMMA, another NO synthase inhibitor, significantly
blocked  both  the  peripheral  and  central  antinoci-
ceptive actions of L-NAME in rats and mice. L-NAME
antinociception  was  also  blocked  by  inhibitors  of
guanilate-cyclase activation  and  potentiated by argi-
nine  and  by  a  cGMP  phosphodiesterase  inhibitor.
These  results  allow  us  to  speculate  that  L-NAME
causes antinociception by acting as a partial agonist,
thus  stimulating  iNOS  activation  in  the  nociceptive
tests used. Furthermore our results draw into  ques-
tion the use of L-NAME alone as a methodological tool
to characterise the nociceptive role of the arginine-
NO-cGMP pathway in  physiopathological processes,
in  the  absence  of  confirmation  with  another  NO
synthase inhibitor.
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